People | September 20, 2024
Shilpa Biologicals appoints Dr. Sridevi Khambhampaty as CEO
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
She brings an overall Techno Commercial experience of 22+ Years in various Organizations
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Reported profit after tax declined 19% year-on-year to Rs 76 crores
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Subscribe To Our Newsletter & Stay Updated
